Cargando…

Involvement of Blnk and Foxo1 in tumor suppression in BCR-ABL1-transformed pro-B cells

Oncogenic Bcr-Abl kinase mimics pre-B cell receptor (pre-BCR) survival signals in BCR-ABL1-positive B-cell acute lymphoblastic leukemia (BCR-ABL1(+) B-ALL), driving B-cell progenitor malignant transformation; thus, defining a particularly unfavorable prognosis for patients. During B-cell development...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Ping, Wang, Yang, Qin, Mengting, Li, Dandan, Odhiambo, Woodvine Otieno, Yuan, Meng, Lv, Zhuangwei, Liu, Chengcheng, Ma, Yunfeng, Dong, Yanying, Ji, Yanhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757083/ https://www.ncbi.nlm.nih.gov/pubmed/33416167 http://dx.doi.org/10.3892/or.2020.7888

Ejemplares similares

Identification and characterization of a murine model of BCR-ABL1(+) acute B-lymphoblastic leukemia with central nervous system metastasis
por: Yu, Xiaozhuo, et al.
Publicado: (2019)

CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models
por: Lv, Zhuangwei, et al.
Publicado: (2020)

RAG enhances BCR‐ABL1‐positive leukemic cell growth through its endonuclease activity in vitro and in vivo
por: Yuan, Meng, et al.
Publicado: (2021)

Inflammation accelerates BCR-ABL1(+) B-ALL development through upregulation of AID
por: Zhang, Ping, et al.
Publicado: (2022)

AID assists DNMT1 to attenuate BCL6 expression through DNA methylation in diffuse large B-cell lymphoma cell lines
por: Jiao, Junna, et al.
Publicado: (2020)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

Aloe-Emodin-Mediated Photodynamic Therapy Attenuates Sepsis-Associated Toxins in Selected Gram-Positive Bacteria In Vitro
por: Otieno, Woodvine, et al.
Publicado: (2021)

A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia
por: Wagle, M, et al.
Publicado: (2016)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Targeting the PTP1B‐Bcr‐Abl1 interaction for the degradation of T315I mutant Bcr‐Abl1 in chronic myeloid leukemia
por: Elgehama, Ahmed, et al.
Publicado: (2022)

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
por: Mian, Afsar Ali, et al.
Publicado: (2021)

Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia
por: Kim, Jaeseung C., et al.
Publicado: (2023)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

A Novel ELISA-Based Peptide Biosensor Assay for Screening ABL1 Activity in vitro: A Challenge for Precision Therapy in BCR-ABL1 and BCR-ABL1 Like Leukemias
por: Montecchini, Oksana, et al.
Publicado: (2021)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene
Publicado: (1995)

GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms
por: Yang, Naery, et al.
Publicado: (2018)

Mechanisms of Resistance to the BCR-ABL1 Allosteric Inhibitor Asciminib
por: Qiang, Wang, et al.
Publicado: (2017)

BCR::ABL1 transcripts and clinical outcome ‐ interrogating the technique
por: Branford, Susan
Publicado: (2022)

BCR-ABL1 transcript decline ratio combined BCR-ABL1(IS) as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia
por: Cai, Zhimei, et al.
Publicado: (2020)

Major Molecular Response Achievement in CML Patients Can Be Predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS Ratio at an Earlier Time Point of Follow-Up than Currently Recommended
por: Huet, Sarah, et al.
Publicado: (2014)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

Identification and characterisation of the immune response properties of Lampetra japonica BLNK
por: Han, Yinglun, et al.
Publicado: (2016)

Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia
por: Zhang, Zhanglin, et al.
Publicado: (2019)

Impact of timely BCR-ABL1 monitoring before allogeneic stem cell transplantation among patients with BCR-ABL1-positive B-acute lymphoblastic leukemia
por: Chong, Siew Lian, et al.
Publicado: (2021)

Inhibition of Aurora Kinase B Is Important for Biologic Activity of the Dual Inhibitors of BCR-ABL and Aurora Kinases R763/AS703569 and PHA-739358 in BCR-ABL Transformed Cells
por: Illert, Anna L., et al.
Publicado: (2014)

Expansion of BCR/ABL1 (+) cells requires PAK2 but not PAK1
por: Edlinger, Leo, et al.
Publicado: (2017)

Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
por: Takeuchi, Asako, et al.
Publicado: (2020)

FISH mapping of Philadelphia negative BCR/ABL1 positive CML
por: Virgili, Anna, et al.
Publicado: (2008)

S6K1 determines the metabolic requirements for BCR-ABL survival
por: Barger, Jennifer F., et al.
Publicado: (2012)

SHP2 Is Required for BCR-ABL1-Induced Hematologic Neoplasia
por: Gu, Shengqing, et al.
Publicado: (2017)

Consensus on BCR‐ABL1 reporting in chronic myeloid leukaemia in the UK
por: Cross, Nicholas C. P., et al.
Publicado: (2018)

Acute Myeloid Leukemia with Concomitant BCR-ABL and NPM1 Mutations
por: Mariotti, Benedetta, et al.
Publicado: (2019)

Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase
por: Choi, Eun-Ji
Publicado: (2023)

BCR: a new target in resistance mediated by BCR/ABL-315I?
por: Haberbosch, Isabella, et al.
Publicado: (2016)

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
por: You, Liangshun, et al.
Publicado: (2016)

Detection of ABL1 kinase domain mutations in therapy-naïve BCR-ABL1-positive acute lymphoblastic leukemia
por: Baer, Constance, et al.
Publicado: (2021)

Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1–transformed acute lymphoblastic leukemia cells
por: Feldhahn, Niklas, et al.
Publicado: (2007)

Chronic myeloid leukemia with an e1a3 BCR-ABL fusion protein: transformation to lymphoid blast crisis
por: Martinez-Serra, Jordi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rtncq122lk87nru40hgbeht43j